Jim Cramer, during a September 3 episode of CNBC's Mad Money, labeled Nuvation Bio (NUVB) as "pure speculation," warning that its value primarily rests on potential future drug performance rather than current earnings. This comes as the stock has been climbing, with Wall Street analysts maintaining an average 12-month price target of $14.5, suggesting approximately 113% upside from its recent price near $6.80. Analysts' optimism is fueled by the company's successful launch of lung cancer drug IBTROZI and its experimental brain cancer drug Safusidenib receiving FDA Fast Track Designation in August 2026 and entering a crucial late-stage trial.